Medical Therapies buys midkine IP
Thursday, 03 July, 2008
Sydney pharma Medical Therapies [ASX: MTY] has completed the purchase of the IP surrounding midkine protein-related technology assets from Japanese company Cell Signals Inc after receiving shareholder approval.
Cell Signals today traded all midkine protein-related IP rights to Medical Therapies, in exchange for 20 million shares of Medical Therapies stock.
These include patents, trademarks, manufacturing information and technical know-how, on top of all Cell Signals' stocks of midkine protein and reagents.
The agreement was announced in April. Midkine is a neurite growth promoting factor, active in oncogenesis and inflammation.
Frequent nightmares accelerate aging, increase risk of death
Nghtmares independently predict faster biological aging and earlier mortality — even after...
Cardiac organoids bring hope for treating heart disease
Australian scientists have developed lab-grown, three-dimensional heart tissues known as cardiac...
Indigenous-led initiative to resurrect the South Island Giant Moa
New Zealand's Ngāi Tahu Research Centre has partnered with Colossal Biosciences and Sir Peter...
